In Parkinson’s disease, toxic clumps of alpha-synuclein protein not only damage brain cells but also weaken the lining of blood vessels, with both processes likely working together to drive disease progression, according to a study by researchers from Binghamton University in New York and Drexel University in Philadelphia. “Parkinson’s…

Women with Parkinson’s disease are far less likely than men to undergo deep brain stimulation (DBS), in part because they are less likely to have reliable support and more likely to worry about being a burden on their loved ones. That’s according to the study, “How Women…

On Monday nights, I am always busy on my computer — often working on this column and sending out reminder emails to my Tuesday walking group. I started this group about three years ago, a couple years after I’d had deep brain stimulation for Parkinson’s disease. These emails…

While on long-term treatment with Abbvie’s experimental oral drug tavapadon, most people with early Parkinson’s disease did not need to start levodopa — the mainstay therapy for the progressive condition — and most individuals already taking levodopa didn’t need to increase their dose. That’s according to new results…

A new experimental oral therapy called VQ-101 successfully reached the brain and increased the activity of a key protective protein in people with Parkinson’s disease, according to early trial results. The Phase 1 study showed that the treatment, developed by Vanqua Bio,…